TRVI
Trevi Therapeutics Inc
NASDAQ: TRVI · HEALTHCARE · BIOTECHNOLOGY
$13.82
-0.14% today
Updated 2026-04-29
Market cap
$1.96B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.32
Dividend yield
—
52W range
$5 – $16
Volume
1.5M
Trevi Therapeutics Inc (TRVI) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $8.41M | $22.23M | $20.49M | $60.00M | $47.13M | $38.48M | $123.02M | $89.40M | $110.90M |
| Cash & equivalents | $8.29M | $22.02M | $17.16M | $57.31M | $45.00M | $36.83M | $12.59M | $32.40M | $34.10M |
| Current assets | $8.39M | $22.16M | $18.79M | $59.55M | $46.27M | $37.96M | $122.62M | $87.55M | $109.43M |
| Total liabilities | $25.82M | $7.45M | $3.18M | $5.46M | $19.85M | $21.40M | $15.56M | $6.86M | $11.26M |
| Current liabilities | $20.39M | $7.13M | $2.68M | $5.20M | $5.55M | $12.72M | $13.40M | $5.82M | $10.51M |
| Long-term debt | $5.12M | $0.00 | $1.10M | — | $13.95M | $8.65M | $2.15M | — | — |
| Shareholder equity | $-17.41M | $14.78M | $17.31M | $54.55M | $27.28M | $17.07M | $107.46M | $82.55M | $99.64M |
| Retained earnings | $-72.16M | $-84.43M | $-109.50M | $-114.22M | $-146.98M | $-180.92M | $-210.07M | $-239.13M | $-287.05M |
| Accounts receivable | $19000.00 | $61000.00 | $184000.00 | $558000.00 | $265000.00 | $241000.00 | — | — | $532000.00 |
| Inventory | $0.00 | $63000.00 | $1.40M | $1.60M | $895000.00 | $-241000.00 | — | — | — |
| Goodwill | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |